BMC cancer · 2026
Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujimoto Akihiro, Ichinose Yuki, Matsuura Kazuo, Mikami Emi, Inohana Wakako, Kurosawa Taeko, Nakame Ayako, Sakakibara Ayaka, Nukui Asami, Asano Aya, Shimada Hiroko, Yokogawa Hideki, Ohara Masahiro, Ishiguro Hiroshi, Hasebe Takahiro, Osaki Akihiko, Saeki Toshiaki
Аннотация
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood.
METHODS: We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers-including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio-were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan-Meier methods and Cox proportional hazards models.
RESULTS: A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS.
CONCLUSIONS: Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.
METHODS: We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers-including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio-were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan-Meier methods and Cox proportional hazards models.
RESULTS: A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS.
CONCLUSIONS: Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.